News   /   Reports

One million doses of Iranian Cov-Iran Barakat vaccine ready for emergency use

Saman Kojouri

Press TV, Tehran

Cov Iran Barakat vaccine developers say one million doses of the country’s first homegrown vaccine have been produced, which will be delivered to the Ministry of Health.

Speaking at press conference the managing director of COV-Iran Barekat vaccine research group Hassan Jalili said production of the vaccine will increase to three million doses next month.

Officials in charge of developing CovIran Barakat vaccine said with the third phase of human trial of the vaccine being almost finished the result shows Iran’s vaccine has effectiveness much higher than expectations and is ready for emergency use after being approved by the health ministry.

Cov-Iran Barakat was unveiled on December 29, 2020, and started to be mass-produced on March 29. Iran is among the first countries which started developing a vaccine against Coronavirus, and now four companies are endeavoring to release their products by September and inoculate the whole population.

Out of 16 vaccine production cases, four cases received a code of ethics and are undergoing clinical trials. It is hoped that another three to four cases will succeed in receiving licenses by September.

The second Iranian Coronavirus vaccine, Razi Cov Pars, which started the clinical trial on February 27, will be mass-produced in early August. Iran is also currently producing vaccines jointly with three countries of Cuba, Russia, and Australia.

Iran started mass vaccination against COVID-19 with the Russian-made Sputnik V vaccine on February 9. Iran says it will soon become one of the world’s important manufacturers of the COVID-19 vaccine.

Cov-Iran Barakat vaccine developers are planning to get the approval from the World Health Organization for the Iranian vaccine so as to be listed as one of the safest Covid 19 vaccines for emergency use.


Press TV’s website can also be accessed at the following alternate addresses:

www.presstv.ir

SHARE THIS ARTICLE
Press TV News Roku